These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Complete protection against P. berghei malaria upon heterologous prime/boost immunization against circumsporozoite protein employing Salmonella type III secretion system and Bordetella adenylate cyclase toxoid. Tartz S; Rüssmann H; Kamanova J; Sebo P; Sturm A; Heussler V; Fleischer B; Jacobs T Vaccine; 2008 Nov; 26(47):5935-43. PubMed ID: 18804138 [TBL] [Abstract][Full Text] [Related]
6. C3d binding to the circumsporozoite protein carboxy-terminus deviates immunity against malaria. Bergmann-Leitner ES; Scheiblhofer S; Weiss R; Duncan EH; Leitner WW; Chen D; Angov E; Khan F; Williams JL; Winter DB; Thalhamer J; Lyon JA; Tsokos GC Int Immunol; 2005 Mar; 17(3):245-55. PubMed ID: 15710912 [TBL] [Abstract][Full Text] [Related]
7. A strong CD8+ T cell response is elicited using the synthetic polypeptide from the C-terminus of the circumsporozoite protein of Plasmodium berghei together with the adjuvant QS-21: quantitative and phenotypic comparison with the vaccine model of irradiated sporozoites. Meraldi V; Romero JF; Kensil C; Corradin G Vaccine; 2005 Apr; 23(21):2801-12. PubMed ID: 15780728 [TBL] [Abstract][Full Text] [Related]
8. [Expression and immunogenicity evaluation of ectodomain and subdomains of Plasmodium berghei apical membrane antigen 1]. Li SL; Zhang DM; Cao Y; Pan WQ Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2007 Feb; 25(1):1-5. PubMed ID: 17639690 [TBL] [Abstract][Full Text] [Related]
9. Cellular and humoral immune effector mechanisms required for sterile protection against sporozoite challenge induced with the novel malaria vaccine candidate CelTOS. Bergmann-Leitner ES; Legler PM; Savranskaya T; Ockenhouse CF; Angov E Vaccine; 2011 Aug; 29(35):5940-9. PubMed ID: 21722682 [TBL] [Abstract][Full Text] [Related]
10. A bicistronic DNA vaccine containing apical membrane antigen 1 and merozoite surface protein 4/5 can prime humoral and cellular immune responses and partially protect mice against virulent Plasmodium chabaudi adami DS malaria. Rainczuk A; Scorza T; Spithill TW; Smooker PM Infect Immun; 2004 Oct; 72(10):5565-73. PubMed ID: 15385453 [TBL] [Abstract][Full Text] [Related]
11. Molecular adjuvants for malaria DNA vaccines based on the modulation of host-cell apoptosis. Bergmann-Leitner ES; Leitner WW; Duncan EH; Savranskaya T; Angov E Vaccine; 2009 Sep; 27(41):5700-8. PubMed ID: 19576940 [TBL] [Abstract][Full Text] [Related]
12. Plasmid DNA vaccines are effective in the absence of IFNgamma. Hassett DE; Zhang J; Whitton JL Virology; 1999 Oct; 263(1):175-83. PubMed ID: 10544092 [TBL] [Abstract][Full Text] [Related]
13. Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. Reyes-Sandoval A; Sridhar S; Berthoud T; Moore AC; Harty JT; Gilbert SC; Gao G; Ertl HC; Wilson JC; Hill AV Eur J Immunol; 2008 Mar; 38(3):732-41. PubMed ID: 18266272 [TBL] [Abstract][Full Text] [Related]
14. Removal of the circumsporozoite protein (CSP) glycosylphosphatidylinositol signal sequence from a CSP DNA vaccine enhances induction of CSP-specific Th2 type immune responses and improvesprotection against malaria infection. Scheiblhofer S; Chen D; Weiss R; Khan F; Mostböck S; Fegeding K; Leitner WW; Thalhamer J; Lyon JA Eur J Immunol; 2001 Mar; 31(3):692-8. PubMed ID: 11241272 [TBL] [Abstract][Full Text] [Related]
15. Immune responses in mice induced by prime-boost schemes of the Plasmodium falciparum apical membrane antigen 1 (PfAMA1)-based DNA, protein and recombinant modified vaccinia Ankara vaccines. Miao J; Li X; Liu Z; Xue C; Bujard H; Cui L Vaccine; 2006 Sep; 24(37-39):6187-98. PubMed ID: 16806600 [TBL] [Abstract][Full Text] [Related]
16. Differential effects of C3d on the immunogenicity of gene gun vaccines encoding Plasmodium falciparum and Plasmodium berghei MSP1(42). Weiss R; Gabler M; Jacobs T; Gilberger TW; Thalhamer J; Scheiblhofer S Vaccine; 2010 Jun; 28(28):4515-22. PubMed ID: 20438877 [TBL] [Abstract][Full Text] [Related]
17. Can malaria DNA vaccines on their own be as immunogenic and protective as prime-boost approaches to immunization? Hoffman SL; Doolan DL Dev Biol (Basel); 2000; 104():121-32. PubMed ID: 11713810 [TBL] [Abstract][Full Text] [Related]
18. Comparison of Plasmodium berghei challenge models for the evaluation of pre-erythrocytic malaria vaccines and their effect on perceived vaccine efficacy. Leitner WW; Bergmann-Leitner ES; Angov E Malar J; 2010 May; 9():145. PubMed ID: 20507620 [TBL] [Abstract][Full Text] [Related]
19. [Construction and expression of Plasmodium berghei chimeric protein in Pichia pastoris and its immunogenicity in mice]. Cao Y; Zhang DM; Pan WQ Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2008 Oct; 26(5):327-31. PubMed ID: 19157293 [TBL] [Abstract][Full Text] [Related]
20. Immunization with a circumsporozoite epitope fused to Bordetella pertussis adenylate cyclase in conjunction with cytotoxic T-lymphocyte-associated antigen 4 blockade confers protection against Plasmodium berghei liver-stage malaria. Tartz S; Kamanova J; Simsova M; Sebo P; Bolte S; Heussler V; Fleischer B; Jacobs T Infect Immun; 2006 Apr; 74(4):2277-85. PubMed ID: 16552058 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]